SEC Tracker
Get the app

Synergy CHC SNYRQ

Synergy CHC Q2 FY25: revenue $8.1M; diluted EPS $0.17

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Synergy CHC reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$8.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income$1.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS$0.17No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$1.5MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$77KNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Synergy CHC files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. Cellectar Biosciences CLRB public float $13M, Jun 30, 2025
  2. Earth Science Tech ETST public float $14M, Mar 31, 2026
  3. GeoVax Labs GOVX public float $14M, Jun 30, 2025
  4. Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old
  5. Cypherpunk Technologies CYPH public float $12M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.